Santhera Pharmaceuticals Holding AG Asset Resilience Ratio
Santhera Pharmaceuticals Holding AG asset resilience ratio. Santhera Pharmaceuticals Holding AG (SANN) has an Asset Resilience Ratio of 27.70% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Santhera Pharmaceuticals Holding AG (SANN) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Santhera Pharmaceuticals Holding AG (2006–2024)
Asset resilience ratio of Santhera Pharmaceuticals Holding AG from 2006 to 2024. This chart shows how Santhera Pharmaceuticals Holding AG's Asset Resilience Ratio has changed over time. Read Santhera Pharmaceuticals Holding AG balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Santhera Pharmaceuticals Holding AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Santhera Pharmaceuticals Holding AG.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF30.37 Million | 27.7% |
| Short-term Investments | CHF0.00 | 0% |
| Total Liquid Assets | CHF30.37 Million | 27.70% |
Asset Resilience Insights
- Very High Liquidity: Santhera Pharmaceuticals Holding AG maintains exceptional liquid asset reserves at 27.70% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Santhera Pharmaceuticals Holding AG Industry Peers by Asset Resilience Ratio
Compare Santhera Pharmaceuticals Holding AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Santhera Pharmaceuticals Holding AG Asset Resilience Ratio by Year (2006–2024)
Santhera Pharmaceuticals Holding AG asset resilience ratio by year from 2006 to 2024. The table below shows the annual Asset Resilience Ratio data for Santhera Pharmaceuticals Holding AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 14.82% | CHF22.59 Million ≈ $28.57 Million |
CHF152.49 Million ≈ $192.79 Million |
-5.11pp |
| 2023-12-31 | 19.92% | CHF21.84 Million ≈ $27.62 Million |
CHF109.63 Million ≈ $138.60 Million |
-3.35pp |
| 2021-12-31 | 23.28% | CHF21.21 Million ≈ $26.81 Million |
CHF91.12 Million ≈ $115.20 Million |
+24.64pp |
| 2018-12-31 | -1.36% | CHF-1.50 Million ≈ $-1.90 Million |
CHF110.29 Million ≈ $139.44 Million |
-13.21pp |
| 2017-12-31 | 11.85% | CHF13.01 Million ≈ $16.45 Million |
CHF109.78 Million ≈ $138.79 Million |
-43.02pp |
| 2016-12-31 | 54.87% | CHF49.81 Million ≈ $62.98 Million |
CHF90.79 Million ≈ $114.79 Million |
+54.81pp |
| 2007-12-31 | 0.06% | CHF81.00K ≈ $102.41K |
CHF144.18 Million ≈ $182.28 Million |
-0.11pp |
| 2006-12-31 | 0.16% | CHF263.00K ≈ $332.50K |
CHF162.39 Million ≈ $205.31 Million |
-- |
About Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pi… Read more